Renewed interest in psychedelics

8b946926-6b0c-4c71-a68b-88fea609f413

Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same? NDRI’s Adjunct Research Fellow Dr Stephen Bright shares his views.

We are in the midst of an international psychedelic science renaissance. Prestigious institutions such as Imperial College, UCLA, New York University and Johns Hopkins Medical School have initiated robust psychedelic research programs (Bright, Williams, & Caldicot, 2017). The classic psychedelic drugs being investigated include Lysergic Acid Diethylamide (LSD), psilocybin (the psychoactive chemical in ‘magic mushrooms’) and Dimethyltryptamine (DMT). This research is providing increasing evidence that psychedelics might be powerful therapeutic tools that could be harnessed in the treatment of depression, anxiety, trauma and substance use disorders (for review, see Bright & Williams, 2018; Nichols, 2016).

Read more: http://connections.edu.au/opinion/renewed-interest-psychedelics-potentially-useful-therapeutic-agents

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search